Kalydeco, also known as ivacaftor, is a medication that has been approved by the FDA for the treatment of cystic fibrosis in patients who have specific genetic mutations. This drug works by targeting the defective protein that causes cystic fibrosis, ultimately improving lung function and reducing the frequency of respiratory infections.

Patients who have been prescribed Kalydeco may experience improvements in their ability to breathe, as well as a decrease in the production of thick mucus that can clog the airways. This can lead to a better quality of life for those living with cystic fibrosis.

It is important to note that Kalydeco is not a cure for cystic fibrosis, but rather a treatment that can help manage the symptoms of the disease. It is typically taken orally, either with or without food, and the dosage will be determined by a healthcare provider based on the individual patient’s needs.

As with any medication, there may be potential side effects associated with Kalydeco. These can include headache, dizziness, nausea, and changes in liver function. It is important for patients to discuss any concerns or side effects with their healthcare provider.

Overall, Kalydeco has been shown to be an effective treatment option for patients with cystic fibrosis who have specific genetic mutations. By targeting the underlying cause of the disease, this medication can help improve lung function and overall quality of life for those living with cystic fibrosis.